With India witnessing a super-surge in Omicron-triggered Covid cases, people across age groups are now rushing to hospitals and healthcare providers asking for a dose of the monoclonal antibody cocktail therapy popularised by former US President Donald Trump in 2020.
Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs).
Announced Strategic Partnership with Mila to Expand AI Capabilities and Functionality of Antibody Development Platform
Advanced Lead Candidates for COVID-19 PolyTope™ Cocktail Therapy, Preclinical Trials Scheduled to Launch in January 2021
VICTORIA, BC, Dec. 21, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA ) (TSXV: IPA) (OTCQB: IPATF) today announced financial results for the second quarter of its 2021 fiscal year ended October 31, 2020.
Q2 Fiscal 2021 Financial Highlights:
Revenue was $4.8 million for the quarter ended October 31, 2020, an increase of $1.6 million, or 50%, compared to $3.2 million in the same quarter last year.
Adjusted EBITDA was $795,159 for the quarter ended October 31, 2020, an increase of $858,577 compared to ($63,418) in the same quarter last year.